The superfamily of G protein-coupled receptors (GPCRs)includes five subtypes of somatostatin receptors, includingSomatostatin Receptor 2 (SSTR2). The SSTR2 gene, which isfound on chromosome 17q25.1, encodes the somatostatinreceptor 2. The hormone somatostatin (SST), which inhibitsboth hormone secretion and gastrointestinal function,activates SSTR2. Additionally, SST and its receptor subtypesinhibit angiogenesis and have anti-proliferative propertiesagainst both malignant and healthy cells. Numerous humantumours have been shown to exhibit significant expressionof somatostatin receptors. IHC revealed thatneuroblastomas, medulloblastomas, paragangliomas,small cell lung malignancies, meningiomas, and breastcancers all had high expression of the somatostatinreceptor 2 antibody. According to one study, a wide rangeof brain and neuroendocrine tumours have elevated andhighly selective expression of the somatostatin receptor 2antibody. Reduced immunohistochemical staining waslinked to an advanced stage of the tumours in anotherstudy that looked at patients with gastroenteropancreaticneuroendocrine neoplasm (GEP-NEN). Furthermore, it wasdiscovered that patients with higher SSTR2 expression hadbetter survival rates, suggesting the potential utility ofSSTR2 as a prognostic indicator for GEP-NEN.